Physician profile
Jonathan D Rowson
NPI 1194729830
$5,272.81
in general payments reported to CMS, 2019-2025
36 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $576 · 2021: $458 · 2022: $379 · 2023: $1,469 · 2024: $657 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,822.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $607.57 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $546.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $455.11 | 2022-2025 | Vraylar, Linzess, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.72 | 2019-2025 | Jardiance |
| Pfizer INC. | $383.86 | 2019-2025 | |
| Lilly USA, LLC | $288.66 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $220.97 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $215.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $180.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $173.55 | 2019-2023 | Trelegy Ellipta |
| Preventric Diagnostics, INC. | $167.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $155.91 | 2019-2022 | |
| Amgen INC. | $136.68 | 2019-2023 | Repatha, Otezla |
| Shield Therapeutics INC | $130.54 | 2024 | |
| Abbott Laboratories | $129.88 | 2023-2025 | Freestyle Libre 3 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rowson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.